NCT06778330 is a NA clinical trial of Dapagliflozin (DAPA) in Heart Failure NYHA Class II, sponsored by Fayoum University.

Who is sponsoring NCT06778330?

NCT06778330 is sponsored by Fayoum University.

What drugs are being tested in NCT06778330?

Interventions in NCT06778330: Dapagliflozin (DAPA), Sildenafil.

What condition does NCT06778330 study?

NCT06778330 studies Heart Failure NYHA Class II.

Is NCT06778330 still recruiting?

NCT06778330 is currently completed. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT06778330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

Completed NA Last updated 3 September 2025

What this trial tests

NA trial testing Dapagliflozin (DAPA) in Heart Failure NYHA Class II in 100 participants. Completed in 1 August 2025.

Timeline

20 January 2025

Primary endpoint
1 August 2025

1 August 2025

Quick facts

Lead sponsor	Fayoum University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	20 January 2025
Primary completion	1 August 2025
Estimated completion	1 August 2025
Sites	1 location across Egypt

Drugs / interventions tested

Dapagliflozin (DAPA) — full drug profile →
Sildenafil (sildenafil) — full drug profile →

Conditions studied

Heart Failure NYHA Class II — all drugs for Heart Failure NYHA Class II →

Sponsor

Fayoum University

Who can join

18 and older, any sex, with Heart Failure NYHA Class II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Sildenafil in Combination with Dapagliflozin Versus Dapagliflozin Monotherapy in the Management of Heart Failure with Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Abdallah EM, Kamal M, Elkhashab K, Mohamed MA, et al · · 2025 · PMID 41304908 · DOI 10.3390/ph18111663

Verify or expand the search:

Other trials of Dapagliflozin (DAPA)

Trials testing the same drug.

NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
NCT06922656 — Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Preven · Phase 4 · not yet recruiting
NCT07120828 — The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity · Phase 4 · completed
NCT07082114 — A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus · Phase 3 · recruiting

Other recruiting trials for Heart Failure NYHA Class II

Currently open trials in the same condition.

NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting
NCT04829617 — Promoting Well-being and Health in Heart Failure · NA · recruiting
NCT03180320 — Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study) · NA · recruiting

Other Fayoum University trials

Trials by the same sponsor.

NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06778330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fayoum University
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06778330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing